MIAMI, FL--(MARKET WIRE)--Jun 22, 2007 -- DOR BioPharma, Inc. (OTC BB:DORB.OB - News) ("DOR" or the "Company"), a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biodefense countermeasures, today announced that its Board of Directors has approved a Shareholder Rights Agreement under which in certain circumstances its stockholders will receive a dividend in the form of preferred stock purchase rights. The Rights Agreement is similar to plans adopted by many other public companies and is not being adopted in response to any current attempt to acquire the company.
